Dr Benjamin George champions accessible cancer care in rural Nebraska, transforming patient support with innovative programs ...

Discover groundbreaking advancements in urologic oncology, including new standards for prostate, kidney, and bladder cancer ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Dr Benjamin George transforms cancer care in rural Nebraska, ensuring accessible, high-quality treatment for patients in ...

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Benjamin George, MD, currently serving as the medical director of oncology at Community Hospital in McCook, Nebraska, and ...

Marija Balic, MD, discusses challenges that remain to the widespread implementation of MRD-guided patient management in TNBC.

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

In a new observational study published in Cancer, commonly prescribed chronic medications did not affect the efficacy of ...

The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...

The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the ...